Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
NELL-1 induces Sca-1+ mesenchymal progenitor cell expansion in models of bone maintenance and repair
Aaron W. James, … , Xinli Zhang, Chia Soo
Aaron W. James, … , Xinli Zhang, Chia Soo
Published June 15, 2017
Citation Information: JCI Insight. 2017;2(12):e92573. https://doi.org/10.1172/jci.insight.92573.
View: Text | PDF
Research Article Bone biology Cell biology

NELL-1 induces Sca-1+ mesenchymal progenitor cell expansion in models of bone maintenance and repair

  • Text
  • PDF
Abstract

NELL-1 is a secreted, osteogenic protein first discovered to control ossification of the cranial skeleton. Recently, NELL-1 has been implicated in bone maintenance. However, the cellular determinants of NELL-1’s bone-forming effects are still unknown. Here, recombinant human NELL-1 (rhNELL-1) implantation was examined in a clinically relevant nonhuman primate lumbar spinal fusion model. Prolonged rhNELL-1 protein release was achieved using an apatite-coated β-tricalcium phosphate carrier, resulting in a local influx of stem cell antigen-1–positive (Sca-1+) mesenchymal progenitor cells (MPCs), and complete osseous fusion across all samples (100% spinal fusion rate). Murine studies revealed that Nell-1 haploinsufficiency results in marked reductions in the numbers of Sca-1+CD45–CD31– bone marrow MPCs associated with low bone mass. Conversely, rhNELL-1 systemic administration in mice showed a marked anabolic effect accompanied by increased numbers of Sca-1+CD45–CD31– bone marrow MPCs. Mechanistically, rhNELL-1 induces Sca-1 transcription among MPCs, in a process requiring intact Wnt/β-catenin signaling. In summary, NELL-1 effectively induces bone formation across small and large animal models either via local implantation or intravenous delivery. NELL-1 induces an expansion of a bone marrow subset of MPCs with Sca-1 expression. These findings provide compelling justification for the clinical translation of a NELL-1–based therapy for local or systemic bone formation.

Authors

Aaron W. James, Jia Shen, Rebecca Tsuei, Alan Nguyen, Kevork Khadarian, Carolyn A. Meyers, Hsin Chuan Pan, Weiming Li, Jin H. Kwak, Greg Asatrian, Cymbeline T. Culiat, Min Lee, Kang Ting, Xinli Zhang, Chia Soo

×

Figure 4

Nell-1 deficiency in mice results in reduced Sca-1+ progenitor cell numbers.

Options: View larger image (or click on image) Download as PowerPoint

Nell-1 deficiency in mice results in reduced Sca-1+ progenitor cell num...
(A) Immunofluorescent staining of CD31–CD45–Sca-1+ cells in mouse bone marrow of WT and Nell-1+/6R mice, analyzed at 3 months of age. From left to right: CD31/CD45+ cells appear green, stem cell antigen 1+ (Sca-1+) cells appear red, CD31/CD45+Sca-1+ cells appear yellow, and on the far right CD31–CD45–Sca-1+ cells appear red after digitally removing all yellow fluorescence. Scale bars: 50 μm. (B) At high magnification, the localization and type of CD31–CD45–Sca-1+ cells (arrows) was revealed, with the majority of cells residing in an intramarrow location, with scattered bone lining cells stained. Dashed white lines indicate margins of trabecular bone. DAPI nuclear counterstain appears blue. Scale bars: 25 μm. (C) Semiquantification of staining presented in A. Six random fields were analyzed per slide with 3 slides analyzed per sample. (D) Representative flow cytometry methods for Sca-1+ cell quantification. After selecting for the CD31–CD45– population (P2), and positive selection for the mesenchymal progenitor cell (MPC) markers CD105 and CD44 (P3), the subpopulation of Sca-1+ (P4) was then selected. (E) Flow cytometric analysis of CD31–CD45–CD105+CD44+Sca-1+ population in mouse bone marrow of WT and Nell-1+/6R mice, analyzed at 3, 7, and 18 months of age. Percentage of cells expressed as CD31–CD45–CD105+CD44+Sca-1+ cells over total CD31–CD45– cells. (F) Flow cytometric analysis of the CD31–CD45–CD105+CD44+Sca-1+ population in mouse bone marrow of CMV-Cre+Nell-1+/+ and CMV-Cre+Nell-1fl/fl mice at 3 months of age. Percentage of cells expressed as CD31–CD45–CD105+CD44+Sca-1+ cells over total CD31–CD45– cells. Data reported as mean ± SEM. *P < 0.05 and **P < 0.01 compared with respective controls. Analyzed using a 2-tailed Student’s t test (C and F) or a 1-way ANOVA followed by a post-hoc Tukey’s test to compare between 2 groups (E).

Copyright © 2022 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts